The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)

Inclusion criteria: * body weight ≥40 kg and ≤125 kg * previously documented CHC genotype 1 infection; * must have a liver biopsy with histology consistent with CHC and no other etiology * if cirrhosis present, must have an ultrasound within 6 months of the screening visit (or between screening and Day 1) with no findings suspicious for hepatocellular carcinoma (HCC) * agree to use acceptable methods of contraception with partner * previously untreated with pegylated-interferon (either alfa-2a or alfa-2b) plus RBV or failing prior treatment with pegylated-interferon (either alfa-2a or alfa-2b) plus RBV Exclusion criteria: * co-infected with the human immunodeficiency virus (HIV) or hepatitis B virus (Hepatitis B surface antigen \[HBsAg\] positive). * required discontinuation of previous interferon or ribavirin regimen for an adverse event (possibly or probably related) * treatment with ribavirin within 90 days and any interferon-alpha, based on the amendment, should be within 1 month prior to screening * treatment with any investigational drug within 30 days of the screening visit in this trial * evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy * diabetic and/or hypertensive with clinically significant ocular examination findings * clinical diagnosis of substance abuse of specified drugs within specified timeframes * any known pre-existing medical condition that could interfere with the participant's participation in and completion of the trial